Investigation announced for Investors in shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) over possible Violations of Securities Laws

An investigation was announced for investors of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) shares over potential securities laws violations by Y-mAbs Therapeutics, Inc. in connection with certain financial statements.

Investors who purchased shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) concerning whether a series of statements by Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

New York based Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Y-mAbs Therapeutics, Inc. reported that its annual Total Revenue rose from $20.75 million in 2020 to $34.89 million in 2021, and that its Net Loss decreased from $119.33 million in 2020 to $117.28 million in 2021.
On October 26, 2022, the FDA posted briefing documents in advance of the vote that identified concerns by FDA scientists regarding data submitted by Y-mAbs Therapeutics, Inc. in support of the company's Biologics License Application (BLA) for its neuroblastoma therapy, omburtamab.

On October 28, 2022, Y-mAbs Therapeutics, Inc. announced the outcome of the meeting of the U.S. Food and Drug Administration ("FDA") Oncologic Drugs Advisory Committee ("ODAC"), which reviewed investigational 131I-omburtamab ("omburtamab") for the treatment of CNS/leptomeningeal metastasis from neuroblastoma. -mAbs Therapeutics, Inc. announced that the committee voted 16 to 0 that the Company had not provided sufficient evidence to conclude that omburtamab improves overall survival.

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) declined to $2.94 per share on November 3, 2022.

Those who purchased shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.